Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab

Comparative Medicine

Volumn 55, Issue 4, 2005, Pages 377-381

  Allen, Kenneth P ^a   Funk, Amy J ^a   Mandrell, Timothy D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; BACITRACIN ZINC; BUPRENORPHINE; CHLORHEXIDINE; CHLORHEXIDINE ACETATE; CORTICOSTEROID; HYDROCORTISONE SODIUM SUCCINATE; IBUPROFEN; NEOMYCIN; PARACETAMOL; POLYMYXIN B; PREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RITUXIMAB; SULTAMICILLIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DISEASE COURSE; ERYTHEMA; HISTOPATHOLOGY; MACACA; NONHUMAN; PROTEIN EXPRESSION; RHESUS MONKEY; SKIN BIOPSY; SKIN DEFECT; SKIN ULCER; TOXIC EPIDERMAL NECROLYSIS;

ABDOMEN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; HINDLIMB; MACACA MULATTA; MONKEY DISEASES; SKIN;

EID: 33645995442     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Amon, R. B. and R. L. Diamond. 1975. Toxic epidermal necrolysis rapid differentiation between staphylococcal-and drug-induced disease. Arch. Dermatol. 111:1433-1437.
2. Anderson, K. C., M. P. Bates, and B. L. Slaughenhoupt. 1984. Expression of human B cell associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424-1433.
3. Bastuji-Garin, S., B. Rzany, R. S. Stern, N. H. Shear, L. Naldi, and J. Roujeau. 1993. Clinical classification of cases of toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129:92-96.
4. Byrd, J. C., T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Pearson, J. K. Waselenko, G. Ling, M. R. Grever, A. J. Grillo-Lopex, J. Rosenberg, L. Kunkel, and I. W. Flinn. 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2153-2164.
5. Chan, H. L., R. S. Stern, K. A. Arndt, J. Langlois, S. S. Jick, H. Ji, and A. M. Walker. 1990. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch. Dermatol. 126:43-47.
6. Coiffier, B., E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Faulard, F. Reyes, and C. Gisselbrecht. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-242.
7. Davis, T. A., C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Morbacher, R. Weaver, S. Dowden, and R. Levy. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 17:1851-1857.
8. Elias, P. M., P. Fritsch, and H. Mittermayer. 1976. Staphylococcal toxic epidermal necrolysis: species and tissue susceptibility and resistance. J. Invest. Dermatol. 66:80-89.
9. Foran, J. M., T. K. Gupta, D. Cunningham, R. A. Popescu, A. H. Goldstone, J. W. Sweetenham, R. Pettengell, P. W. M. Johnson, E. Bessell, B. Hancock, K. Summers, J. Hughes, A. Z. S. Rohatiner, and T. A. Lister. 2000. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:81-88.
10. Fritsch, P. O. and A. Sidoroff. 2000. Drug-induced Stevens-Johnson sydrome/toxic epidermal necrolysis. Am. J. Clin. Dermatol. 6:349-360.
11. Carman, R. H., C. Reed, and D. W. Blick. 1979. Toxic epidermal necrolysis in a monkey (Macaca fascicularis). Vet. Pathol. 16:81-88.
12. Genetech, Inc. 2003. Product information-rituxan full prescribing information. Genetech, Inc., San Francisco.
13. Ghislain, P. D. and J. C. Roujeau. 2002. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. Online J. 8:5.
14. Johnson, P. W. M. and M. J. Glennie. 2001. Rituximab: mechanisms and applications. Br. J. Cancer. 85:1619-1623.
15. Lowndes, S., A. Darby, G. Mead, and A. Lister. 2002. Stevens-Johnson syndrome after treatment with rituximab. Ann. Oncol. 13:1948-1950.
16. Lyell, A. 1956. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol. 68:355-61.
17. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. Liles, B. K. Dallaire, K. Wey, I. Royston, T. Davis, and R. Levy. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195.
18. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, V. Jail, A. D. Ho, J. Lister, K. Wey, D. Shen, and B. K. Dallaire. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-2833.
19. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
20. O'Brien, S. M., H. Kantarjian, D. A. Thomas, F. J. Giles, E. J. Freireich, J. Cortes, S. Lerner, and M. J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2165-2170.
21. Roujeau, J. C. 1997. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J. Dermatol. 24:726-729.
22. Stashenko, P., L. M. Nadler, R. Hardy, and S. F. Schlossman. 1980. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125:1678-1685.
23. Streilein, J. W. 1972. Analysis of graft-versus-host disease in Syrian hamsters. IV. The refractory state and immunologie competence. J. Exp. Med. 135:567-578.
24. Wintroub, B. U. and R. Stern. 1985. Cutaneous drug reactions: pathogenesis and clinical classification. J. Am. Acad. Dermatol. 2:167-179.
25. Wolkenstein, P. and J. Revuz. 2000. Toxic epidermal necrolysis. Dermatol. Clin. 18:485-495.
26. Yager, J. A. and D. W. Scott. 1985. The skin and appendages, p. 458-461. In K. V. F. Jubb, P. C. Kennedy, and N. Palmer (ed.), Pathology of domestic animals. Academic Press, Inc., New York.
27. Yeruham, I., S. Perl, and D. Elad. 1999. Nine cases of idiopathic toxic epidermal necrolysis in cattle in Israel. Zentralbl. Veterinarmed. B 7:493-498.